CAB

BioAtla to Participate in the Jefferies Global Healthcare Conference

Retrieved on: 
星期三, 五月 29, 2024
Conditional, Conference, CAB, Therapy, SAN

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held in New York, NY June 4–6, 2024.

Key Points: 
  • SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held in New York, NY June 4–6, 2024.

Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy

Retrieved on: 
星期二, 五月 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Managed Care, Health, Genetics, Clinical Trials, Patient, FSHD, Hospital for Sick Children, UCLA, MSCL, Tic disorder, FDA, Drug development, FAAN, Myotonic dystrophy, DMD, CAB, CMO, Shirin David, VCU, Professor, Hospital, Duchenne muscular dystrophy, Facioscapulohumeral muscular dystrophy, CRISPR, Therapy, TSX, OTCQB, Muscular dystrophy, Pharmaceutical industry

“The formation of this Clinical Advisory Board marks a major development step for Satellos as we continue our evolution in becoming a clinical stage drug development company,” said Frank Gleeson, Co-founder and CEO of Satellos.

Key Points: 
  • “The formation of this Clinical Advisory Board marks a major development step for Satellos as we continue our evolution in becoming a clinical stage drug development company,” said Frank Gleeson, Co-founder and CEO of Satellos.
  • Research in his laboratory focuses on utilizing genome editing technologies like CRISPR for the development of therapeutic approaches for neurogenetic disorders.
  • Francesco Muntoni, M.D., Director, Dubowitz Neuromuscular Centre, Great Ormond Street UCL Institute of Child Health, is focused on advancing novel therapeutics in translational and clinical research for pediatric neuromuscular disorders, especially Duchenne muscular dystrophy.
  • Dr. Shieh’s principal clinical interests include Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD), and myotonic dystrophy.

BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
星期四, 五月 23, 2024
Conditional, Patient, PFS, SAN, NSCLC, CAB, Ipilimumab, PD-1, ASCO, Poster, Carcinoma, Society, Observation, BRAF, Therapy, DLT, Nivolumab, Annual general meeting, Pharmaceutical industry

SAN DIEGO, May 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced expanded data at an upcoming presentation entitled, “Phase 1 study of evalstotug (BA3071), an anti-CTLA-4 Conditionally Active Biologic, in combination with nivolumab in advanced solid tumors”, demonstrating confirmed responses with a potentially differentiated tolerability profile with the Company’s novel, conditionally active anti-CTLA-4 agent, evalstotug, in combination with anti-PD-1 therapy. The poster will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting at the McCormick Place Convention Center in Chicago, Illinois on Saturday, June 1, 2024.

Key Points: 
  • The poster will be presented at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting at the McCormick Place Convention Center in Chicago, Illinois on Saturday, June 1, 2024.
  • “Given the emerging clinical profile observed, we believe evalstotug has the potential to be best-in-class CTLA-4 antibody and holds the promise to be used as often as a PD-1 inhibitor,” said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc. “Strikingly, we have observed prolonged PFS of greater than 10 months and confirmed responses at high doses (350 mg), of evalstotug, suggesting increased exposure of CTLA-4 blockade in combination with PD-1 inhibition drives clinical benefit.
  • We continue to enroll in the Phase 2 first-line melanoma and mutated NSCLC combination cohorts at the 700 mg flat dose and we anticipate moving to the 1 gram flat dose in June following clearance of the DLT observation period and remain on track for monotherapy and combination data readouts later this year.
  • We anticipate enabling a Phase 3 trial of evalstotug in first-line metastatic or unresectable BRAF-mutated melanoma in the second half of this year.

BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

Retrieved on: 
星期二, 五月 14, 2024
Conditional, Patient, Pembrolizumab, Neck, SCCHN, FDA, IND, UPS, Anticipation, EGFR, Head, SAN, NSCLC, ADC, CAB, PD-1, Nextgen, Neoplasm, PR, Observation, Research, BRAF, Therapy, G&A, Webcast, DLT, Pharmaceutical industry

Research and development (R&D) expenses were $18.9 million for the quarter ended March 31, 2024 compared to $21.7 million for the same quarter in 2023.

Key Points: 
  • Research and development (R&D) expenses were $18.9 million for the quarter ended March 31, 2024 compared to $21.7 million for the same quarter in 2023.
  • General and administrative (G&A) expenses were $5.6 million for the quarter ended March 31, 2024 compared to $7.2 million for the same quarter in 2023.
  • Net loss for the quarter ended March 31, 2024 was $23.2 million compared to a net loss of $27.5 million for the same quarter in 2023.
  • Cash used for the quarter ended March 31, 2024 included approximately $5.0 million in annual payments that typically only occur during our first fiscal quarter.

BioAtla to Participate in the Citizens JMP Life Sciences Conference

Retrieved on: 
星期三, 五月 8, 2024
Citizenship, Therapy, Conference, SAN, CAB, Conditional

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Citizens JMP Life Sciences Conference, to be held in New York, NY May 13-14, 2024.

Key Points: 
  • SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Citizens JMP Life Sciences Conference, to be held in New York, NY May 13-14, 2024.

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

Retrieved on: 
星期二, 五月 7, 2024
News, Press release, Therapy, Webcast, SAN, CAB, Conditional

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 14, 2024 at 4:30 p.m.

Key Points: 
  • SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 14, 2024 at 4:30 p.m.
  • ET to discuss its financial results for the first quarter ended March 31, 2024 and provide business highlights.
  • The press release with the financial results will be accessible prior to the conference call through “ News Releases ” in the News & Events section of the company’s website.
  • A replay of the call will also be available through “ Events & Presentations ” in the Investors section of the company’s website.

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

Retrieved on: 
星期一, 五月 6, 2024
FDA, Immortalised cell line, CAB, Food, Brentuximab vedotin, IND, Therapy, ADC, Therapeutic index, Conditional, Serum, Toxicity, Nextgen, SAN, Pharmaceutical industry

ADC is a promising treatment modality with broad applicability across multiple tumor indications.

Key Points: 
  • ADC is a promising treatment modality with broad applicability across multiple tumor indications.
  • The CAB technology is designed to eliminate or reduce both on-target, off-tumor and off-target, off-tumor toxicities.
  • At the AACR Annual Meeting in April 2024, data showed differentiated anti-Nectin-4-ADC via in vitro and in vivo characterization of its novel next-generation carbohydrate linker system.
  • The NextGen linker system helped eliminate off-target, off-tumor toxicity with substantially improved serum stability and increased hydophilicity thereby improving potency.

Phoenix Children's Unveils "Wonder And Wander," a 407-Foot Mural to Advance Hope and Healing for Patient Families

Retrieved on: 
星期三, 五月 1, 2024
Pixart, Phoenix Children's Hospital, Hope, Hospital, CAB, Heart, Chairperson, Trauma, Tree, Patient, Child, Lenhardt, Hughes, Anxiety, Sibling

PHOENIX, May 1, 2024 /PRNewswire/ -- Phoenix Children's today unveiled a 407-foot commissioned mural that has transformed a heavily trafficked corridor into a captivating and exciting journey for children and their families.

Key Points: 
  • PHOENIX, May 1, 2024 /PRNewswire/ -- Phoenix Children's today unveiled a 407-foot commissioned mural that has transformed a heavily trafficked corridor into a captivating and exciting journey for children and their families.
  • The installation is a collaboration between Phoenix Children's and RxART , a nonprofit organization that aims to help children heal through the power of visual art.
  • Inspired by RxART's mission, Phoenix Children's Board Chair and RxART Board Member David Lenhardt worked closely with the organization to create an art installation at Phoenix Children's Hospital – Thomas Campus.
  • "I am so grateful for RxART and especially for Shara, who put her heart and soul into creating the perfect piece for Phoenix Children's and the families we serve."

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
星期三, 四月 24, 2024
ASCO, CAB, Therapy, Society, SAN, Nivolumab, Conditional, Pharmaceutical industry

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.

Key Points: 
  • SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.
  • Phase 1 study of BA3071, an anti-CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors

Sevco Security Announced the Launch of a Customer Advisory Board

Retrieved on: 
星期四, 四月 11, 2024
Software, Technology, Security, Internet, Learning, Argo Group, Risk, CAB, Customer advisory council, Intelligence, Environment, SVP, NSA, Intuit, Enterprise, AWS, Organization, Risk management

Sevco Security , the cloud-native Cyber Asset Attack Surface Management (CAASM) platform that delivers the industry’s most accurate, continuously updated security asset inventory to better protect organizations, today announced the launch of its inaugural Customer Advisory Board (CAB).

Key Points: 
  • Sevco Security , the cloud-native Cyber Asset Attack Surface Management (CAASM) platform that delivers the industry’s most accurate, continuously updated security asset inventory to better protect organizations, today announced the launch of its inaugural Customer Advisory Board (CAB).
  • “We have seen a tremendous benefit in bringing these industry experts together and learning from them each day,” said Brian Contos, Chief Strategy Officer at Sevco.
  • By pulling in more data on users, software, and vulnerabilities in customer environments, Sevco is able to provide deeper context on the risks and business impacts of the assets security teams are charged with protecting.
  • My team can then leverage this knowledge to quickly make informed decisions to protect both our organization and customers.”
    Some of Sevco’s Customer Advisory Board members include:
    Albert Attias, Senior Director of Enterprise Security, Workday
    Brandon Pinzon, SVP and Chief Security Officer, Argo Group
    To learn more about Sevco’s Customer Advisory Board and its current members, please visit: sevcosecurity.com/about-us/